{"doi":"10.1016/j.celrep.2023.112599","title":"Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression","abstract":"Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we identify a heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist (SNP) vaccine prime and a chimp adenovirus (ChAdOx1) vaccine boost that elicits potent CD8 T cells and tumor regression. ChAdOx1 administered intravenously (i.v.) had 4-fold higher antigen-specific CD8 T cell responses than mice boosted by the intramuscular (i.m.) route. In the therapeutic MC38 tumor model, i.v. heterologous prime-boost vaccination enhances regression compared with ChAdOx1 alone. Remarkably, i.v. boosting with a ChAdOx1 vector encoding an irrelevant antigen also mediates tumor regression, which is dependent on type I IFN signaling. Single-cell RNA sequencing of the tumor myeloid compartment shows that i.v. ChAdOx1 reduces the frequency of immunosuppressive Chil3 monocytes and activates cross-presenting type 1 conventional dendritic cells (cDC1s). The dual effect of i.v. ChAdOx1 vaccination enhancing CD8 T cells and modulating the TME represents a translatable paradigm for enhancing anti-tumor immunity in humans.","journal":"Cell Reports","year":2023,"id":325440,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":31,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9562,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":232569,"name":"Faezzah Baharom","orcid":"0000-0003-4513-3600","position":1,"is_corresponding":false},{"id":7813,"name":"Ahad Khalilnezhad","orcid":"0000-0001-6492-0517","position":2,"is_corresponding":false},{"id":316542,"name":"Sloane Christian Fussell","orcid":"0009-0009-8628-8335","position":3,"is_corresponding":false},{"id":625477,"name":"Dalton Hermans","orcid":"0000-0002-7913-1198","position":4,"is_corresponding":false},{"id":871875,"name":"Alexander M. Schrager","orcid":null,"position":5,"is_corresponding":false},{"id":234454,"name":"Kennedy K.S. Tobin","orcid":null,"position":6,"is_corresponding":false},{"id":234451,"name":"Geoffrey M. Lynn","orcid":null,"position":7,"is_corresponding":false},{"id":843091,"name":"Shabnam Khalilnezhad","orcid":null,"position":8,"is_corresponding":false},{"id":71133,"name":"Florent Ginhoux","orcid":"0000-0002-2857-7755","position":9,"is_corresponding":false},{"id":896384,"name":"Benoit J. Van den Eynde","orcid":"0000-0002-4995-3270","position":10,"is_corresponding":false},{"id":1043049,"name":"Carol S. Leung","orcid":"0000-0002-1545-7228","position":11,"is_corresponding":false},{"id":232587,"name":"Andrew S. Ishizuka","orcid":"0000-0002-3024-7536","position":12,"is_corresponding":false},{"id":225156,"name":"Robert A. Seder","orcid":"0000-0003-3133-0849","position":13,"is_corresponding":false},{"id":234452,"name":"Ramiro A. Ramirez-Valdez","orcid":null,"position":0,"is_corresponding":true}],"reference_count":47,"raw_metadata":null,"created_at":"2026-07-19T01:08:22.919783Z","pmid":"37279110","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}